Roche Holding Ltd · SIX:RO
Roche — Jefferies London Healthcare Conference 2024
22 slides from Roche's conference presentation, Nov 20, 2024
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Opening remarks
Opening remarks Alan Hippe | CFO Roche Group Jefferies London Healthcare Conference 20 November 2024
Slide 4: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 5: YTD Sep 2024: Strong growth in both divisions
YTD Sep 2024: Strong growth in both divisions Q3 without significant COVID-19 impact Pharma* Diagnostics* Quarterly sales evolution 2022-2024 Quarterly sales evolution 2022-2024 % CER % CER 30% 30% +24% 20% 20% +12% +9% +10% +10% +9% +9% +7% +7% +7% +7% +8% +8% +7% +8% +8% +9% +7% 10% +6% +4% 10% +3
Slide 6: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio Significant milestones achieved in Q3 to enable future growth +5% YTD Sep 2024 sales Diagnostics: +8% base business growth (CHFbn, YoY CER growth) (+8%)* Significant launches upcoming Itovebi: US approval in 1L PIK3CA-mut HR+ BC 10.7 Tecentriq Hybreza: US ap
Slide 7: Young portfolio to drive growth in the near- to mid-term
Young portfolio to drive growth in the near- to mid-term 2024 NME update: US approval for Itovebi (inavolisib) in HR+ breast cancer and PiaSky in PNH achieved CHFm % of Pharma Sales2 20.0 56% 18.0 50% 16.0 42% 14.0 12.0 34% 10.0 8.0 1 6.0 4.0 2.0 0.0 YTD Sep 2021 YTD Sep 2022 YTD Sep 2023 YTD Sep 20
Slide 8: A solid base to deliver future growth
A solid base to deliver future growth Pipeline and business development to add significant upside potential illustrative Business development • BD to accelerate pipeline portfolio • In-house pipeline with upside Pharma pipeline potential • On-market Pharma portfolio to deliver growth until 2027 Sale
Slide 9: 2024 guidance raised at HY
2024 guidance raised at HY Core EPS guidance raised from “broadly in line with sales” to “high single digit Core EPS growth” Group sales growth1 Mid single digit sales growth High single digit Core EPS growth Core EPS growth1 excl. impact from resolution of tax disputes in 2023 Dividend outlook Furt
Slide 10: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 11: Our new Pharma Strategy
Our new Pharma Strategy Providing clarity and intentional focus to leverage our scientific strengths and impact patients globally Where we play: Priority Therapeutic Areas How we succeed: Core capabilities Neurology Oncology/ Hematology Modalities & Devices Manufacturing Technologies Ophthalmology I
Slide 12: Selecting our therapeutic areas and focus disease areas
Selecting our therapeutic areas and focus disease areas Our focus considers societal burden and transformational potential, as well as Roche’s current capabilities External drivers Internal drivers Burden of disease and Potential to yield Roche’s strengths societal costs transformative medicines ● D
Slide 13: Embracing bold objectives: Our 2030 R&D ambitions
Embracing bold objectives: Our 2030 R&D ambitions Toward top quartile industry performance Increase average peak year sales of Increase Ph 0 initiations/yr1: Increase Ph III success rate: pipeline assets: +50% +22%p +50% Success Volume Value rate Effectiveness R&D Excellence Costs Cycle time Efficie
Slide 14: Meaningful improvements achieved in 2024
Meaningful improvements achieved in 2024 R&D Excellence enables us to reallocate resources to new projects, new deals & accelerate priority assets Added 5 assets trough high-value CHF +0.24bn average peak year sales per Recent team-assessed PTS for partnerships and 8 assets from project trough termi
Slide 15: Pharma pipeline evolution since Pharma Day 2023
Pharma pipeline evolution since Pharma Day 2023 Since Pharma Day 2023 17 NMEs were added and 26 NMEs removed, resulting in a higher impact portfolio Pipeline changes since Q2’23 siRNA targeting AGT in hypertension 8 -8 17 Additions 81 4 -3 1 • 8 Ph I/Ph II NMEs acquired as -5 3 -4 2 part of high val
Slide 16: Pipeline acceleration through partnering and acquisitions
Pipeline acceleration through partnering and acquisitions Key deals completed to complement our pipeline across the Pharma focus therapeutic areas * Dual GLP- Molecular 1/GIP RA & siRNA Anti-TL1A in Wnt agonist Zinc finger glue CDKi ADCs in PYY targeting inflammatory in molecules in degraders in por
Slide 17: Leveraging AI to increase overall Pharma productivity
Data & AI Leveraging AI to increase overall Pharma productivity Selected AI use cases along the value chain Regulatory & Manufacturing Drug development Commercialization reimbursement & distribution gRED’s ‘Lab-in-a-loop’ Document writing Digital twin Predictive alerts • AI/ML: Computational • Gen A
Slide 18: One more IR event in 2024: Roche's Digitalization Day
One more IR event in 2024: Roche’s Digitalization Day on Nov 25th CVM/EASD Pharma Day Neurology/CTAD Digitalization Day Sep 13 Sep 30 Oct 31 Nov 25 • Key data presented at EASD: • Group & Pharma strategy • Overview of the Roche • Roche digital efforts in Pharma • CT-388 (Ph I cohort 11 & 12 in updat
Slide 19: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 20: Peak sales potential of key pipeline assets (NMEs and LEs)
Peak sales potential of key pipeline assets (NMEs and LEs) New Molecular Entities (NME) giredestrant prasinezumab astegolimab HR+ BC Parkinson's disease COPD inavolisib fenebrutinib ASO Factor B • 7+ NMEs with CHF >3bn peak Pi3Km BC RMS, PPMS IgAN sales potential per asset divarasib Elevidys1 vamiki
Slide 21: 2025: Significant key newsflow ahead
2025: Significant key newsflow ahead* Compound Indication Milestone inavolisib + palbociclib + fulvestrant 1L PIK3CA-mut HR+ BC EU approval Columvi + GemOx 2L+ DLBCL US/EU approval Lunsumio SC 3L+ FL US/EU approval Elevidys DMD EU approval Gazyva Lupus nephritis US/EU filing; US approval Regulatory
Slide 22: Doing now what patients need next
Doing now what patients need next
Roche Holding — Jefferies London Healthcare Conference 2024 on 6ix